APA (7th ed.) Citation

L, S., M, F., Y, K., DS, H., DP, M., J, T., . . . F, P. (2026). Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. Clinical colorectal cancer. https://doi.org/10.1016/j.clcc.2026.04.003

Chicago Style (17th ed.) Citation

L, Salvatore, et al. "Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer." Clinical Colorectal Cancer 2026. https://doi.org/10.1016/j.clcc.2026.04.003.

MLA (9th ed.) Citation

L, Salvatore, et al. "Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer." Clinical Colorectal Cancer, 2026, https://doi.org/10.1016/j.clcc.2026.04.003.